These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

396 related items for PubMed ID: 19616339

  • 21. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease.
    Papatheodoridis GV, Dimou E, Laras A, Papadimitropoulos V, Hadziyannis SJ.
    Hepatology; 2002 Jul; 36(1):219-26. PubMed ID: 12085368
    [Abstract] [Full Text] [Related]

  • 22. Clinical improvement in patients with decompensated liver disease caused by hepatitis B after treatment with lamivudine.
    Sponseller CA, Bacon BR, Di Bisceglie AM.
    Liver Transpl; 2000 Nov; 6(6):715-20. PubMed ID: 11084057
    [Abstract] [Full Text] [Related]

  • 23. Long-term lamivudine treatment achieves regression of advanced liver fibrosis/cirrhosis in patients with chronic hepatitis B.
    Xu B, Lin L, Xu G, Zhuang Y, Guo Q, Liu Y, Wang H, Zhou X, Wu S, Bao S, Cai W, Xie Q.
    J Gastroenterol Hepatol; 2015 Feb; 30(2):372-8. PubMed ID: 25167956
    [Abstract] [Full Text] [Related]

  • 24. Prognosis of hepatitis B-related liver cirrhosis in the era of oral nucleos(t)ide analog antiviral agents.
    Kim CH, Um SH, Seo YS, Jung JY, Kim JD, Yim HJ, Keum B, Kim YS, Jeen YT, Lee HS, Chun HJ, Kim CD, Ryu HS.
    J Gastroenterol Hepatol; 2012 Oct; 27(10):1589-95. PubMed ID: 22554121
    [Abstract] [Full Text] [Related]

  • 25. Virological and biochemical relapse after discontinuation of lamivudine monotherapy for chronic hepatitis B in Japan: comparison with breakthrough hepatitis during long-term treatment.
    Akuta N, Suzuki F, Kobayashi M, Matsuda M, Sato J, Suzuki Y, Sezaki H, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.
    Intervirology; 2005 Oct; 48(2-3):174-82. PubMed ID: 15812192
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. HBV-DNA suppression and disease course in HBV cirrhosis patients on long-term lamivudine therapy.
    Di Marco V, Di Stefano R, Ferraro D, Almasio PL, Bonura C, Giglio M, Parisi P, Cappello M, Alaimo G, Craxì A.
    Antivir Ther; 2005 Oct; 10(3):431-9. PubMed ID: 15918334
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. [Durability of HBeAg seroconversion in lamivudine treatment of chronic hepatitis B patients].
    Zhu M, Xu B, Yao GB.
    Zhonghua Gan Zang Bing Za Zhi; 2005 Jul; 13(7):534-6. PubMed ID: 16042894
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Stopping lamivudine therapy after biochemical breakthrough may be a feasible option in selected HBeAg-positive patients.
    Jang JW, Choi JY, Bae SH, Yoon SK, Kim CW, Nam SW, Lee CD, Lee YS, Cha SB, Chung KW.
    J Med Virol; 2005 Nov; 77(3):367-73. PubMed ID: 16173025
    [Abstract] [Full Text] [Related]

  • 33. A higher alanine aminotransferase level correlates with earlier hepatitis B e antigen seroconversion in lamivudine-treated chronic hepatitis B patients.
    Tseng TC, Liu CJ, Wang CC, Chen PJ, Lai MY, Kao JH, Chen DS.
    Liver Int; 2008 Aug; 28(7):1034-41. PubMed ID: 18492018
    [Abstract] [Full Text] [Related]

  • 34. Effect of long-term lamivudine in chronic hepatitis B virus-infected children.
    Ozgenç F, Arikan C, Sertoz RY, Nart D, Aydogdu S, Yagci RV.
    Antivir Ther; 2004 Oct; 9(5):729-32. PubMed ID: 15535410
    [Abstract] [Full Text] [Related]

  • 35. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B.
    Villeneuve JP, Condreay LD, Willems B, Pomier-Layrargues G, Fenyves D, Bilodeau M, Leduc R, Peltekian K, Wong F, Margulies M, Heathcote EJ.
    Hepatology; 2000 Jan; 31(1):207-10. PubMed ID: 10613747
    [Abstract] [Full Text] [Related]

  • 36. Short-term lamivudine therapy in HBeAg-negative chronic active hepatitis B in Taiwan.
    Chien RN, Liaw YF.
    Antivir Ther; 2006 Jan; 11(7):947-52. PubMed ID: 17302259
    [Abstract] [Full Text] [Related]

  • 37. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease.
    Yuen MF, Seto WK, Chow DH, Tsui K, Wong DK, Ngai VW, Wong BC, Fung J, Yuen JC, Lai CL.
    Antivir Ther; 2007 Jan; 12(8):1295-303. PubMed ID: 18240869
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension.
    Afdhal N, Everson GT, Calleja JL, McCaughan GW, Bosch J, Brainard DM, McHutchison JG, De-Oertel S, An D, Charlton M, Reddy KR, Asselah T, Gane E, Curry MP, Forns X.
    J Viral Hepat; 2017 Oct; 24(10):823-831. PubMed ID: 28295923
    [Abstract] [Full Text] [Related]

  • 40. Captopril reduces portal pressure effectively in portal hypertensive patients with low portal venous velocity.
    Baik SK, Park DH, Kim MY, Choi YJ, Kim HS, Lee DK, Kwon SO, Kim YJ, Park JW, Chang SJ.
    J Gastroenterol; 2003 Oct; 38(12):1150-4. PubMed ID: 14714252
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.